BioHarvest Sciences (NASDAQ:BHST) Issues Quarterly Earnings Results

BioHarvest Sciences (NASDAQ:BHST) announced its quarterly earnings results on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02, Zacks reports. BioHarvest Sciences had a negative net margin of 32.54% and a negative return on equity of 102.36%. The firm had revenue of $8.51 million during the quarter, compared to analysts’ expectations of $8.50 million.

Here are the key takeaways from BioHarvest Sciences’ conference call:

• BioHarvest reported Q1 2026 revenue of $8.5 million, up 8% year over year, with gross margin holding near 59%. Net loss was $2.6 million and adjusted EBITDA loss was $1.2 million, roughly in line with last year.
• The company highlighted major progress in its CDMO pipeline, including completion of stage 1 for both a rare fragrance ingredient and SaffronTech’s saffron program, and the signing of a $1.2 million stage 2 fragrance contract.
• Management said the fragrance program has meaningful long-term upside, with BioHarvest retaining 20% ownership of the developed compositions and expecting commercialization to begin in the second half of 2027. They also reiterated a 2026 CDMO revenue guide of $12 million to $14 million.
• In the D2C business, Q1 was described as a “reset quarter” as the company reduced and reworked marketing spend, which weighed on near-term growth. Management said the full benefits of the new approach should show up more meaningfully in the second half of the year.
• VINIA Blood Flow Hydration showed strong early traction, with management citing high customer ratings, growing sales on Amazon and TikTok, and rising seasonality benefits ahead. The company kept full-year D2C revenue guidance at $38 million to $42 million and said it remains focused on improving LTV/CAC efficiency.

BioHarvest Sciences Trading Down 1.4%

Shares of BHST traded down $0.06 during trading hours on Friday, hitting $4.10. 24,793 shares of the stock were exchanged, compared to its average volume of 37,452. BioHarvest Sciences has a fifty-two week low of $3.57 and a fifty-two week high of $12.80. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.97 and a quick ratio of 3.38. The business has a 50-day moving average of $4.26 and a 200-day moving average of $5.29. The firm has a market capitalization of $80.43 million, a P/E ratio of -6.95 and a beta of 0.81.

Institutional Investors Weigh In On BioHarvest Sciences

Large investors have recently modified their holdings of the company. Geode Capital Management LLC acquired a new stake in BioHarvest Sciences in the fourth quarter worth $61,000. Quadrature Capital Ltd acquired a new stake in BioHarvest Sciences in the fourth quarter worth $140,000. Jane Street Group LLC acquired a new stake in BioHarvest Sciences in the fourth quarter worth $145,000. XTX Topco Ltd acquired a new stake in BioHarvest Sciences in the fourth quarter worth $173,000. Finally, Alyeska Investment Group L.P. acquired a new stake in BioHarvest Sciences in the fourth quarter worth $3,929,000.

More BioHarvest Sciences News

Here are the key news stories impacting BioHarvest Sciences this week:

• Positive Sentiment: First-quarter revenue rose 8% year over year to about $8.5 million, slightly ahead of estimates, while EPS matched expectations at a loss of $0.11 per share. BioHarvest Sciences earnings report
• Positive Sentiment: The company said its CDMO business grew 135% year over year in the quarter and highlighted progress on fragrance and saffron projects, which supports its growth narrative. BioHarvest Sciences Q1 2026 Financial Results and Business Update
• Positive Sentiment: Management reaffirmed full-year revenue guidance of $42 million to $48 million and separately outlined 2026 revenue expectations of $38 million to $42 million for direct-to-consumer and $12 million to $14 million for CDMO activity. Seeking Alpha revenue outlook article
• Neutral Sentiment: The company also said its VINIA brand customer base reached 90,000 active users by the end of April and that it is holding a conference call and filing Q1 financials, reinforcing the latest disclosure rather than introducing a new catalyst. BioHarvest Sciences files Q1 2026 financials
• Negative Sentiment: Despite revenue progress, BHST remains unprofitable, and management’s growth story may not be enough to offset concern over ongoing losses and negative margins in the near term. Zacks earnings recap

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of BioHarvest Sciences in a research report on Friday, March 27th. Roth Mkm began coverage on shares of BioHarvest Sciences in a research report on Thursday, February 19th. They set a “buy” rating and a $10.00 price objective for the company. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, BioHarvest Sciences has a consensus rating of “Hold” and an average price target of $10.00.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.